12:00 AM
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HIV/AIDS vaccine: Additional Phase IIa data

GeoVax reported additional data from the double-blind, placebo-controlled, U.S. and Peruvian Phase IIa HVTN 205 trial in 299 healthy, uninfected volunteers showing that HIV gp140 IgG antibody titers in patients who received the company's HIV-1 DNA vaccine as a primer followed by the HIV-1 MVA vaccine as a booster declined by less than 3-fold at 6 months after the last vaccination....

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >